Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shigematsu, H.
Right arrow Articles by Gazdar, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shigematsu, H.
Right arrow Articles by Gazdar, A. F.
[Cancer Research 65, 1642-1646, March 1, 2005]
© 2005 American Association for Cancer Research

Priority Reports

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Hisayuki Shigematsu1,9, Takao Takahashi1, Masaharu Nomura1, Kuntal Majmudar1, Makoto Suzuki5, Huei Lee6, Ignacio I. Wistuba7, Kwun M. Fong8, Shinichi Toyooka9, Nobuyoshi Shimizu9, Takehiko Fujisawa5, John D. Minna1,2,3 and Adi F. Gazdar1,4

1 Hamon Center for Therapeutic Oncology Research, Departments of 2 Internal Medicine, 3 Pharmacology, and 4 Pathology, University of Texas Southwestern Medical Center, Dallas, Texas; 5 Department of Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan; 6 Institute of Medical and Molecular Toxicology, Chung Shan Medical University, Taichung, Taiwan; 7 Department of Pathology and Thoracic/Head and Neck Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, Texas; 8 Prince Charles Hospital, Brisbane, Australia; and 9 Department of Cancer and Thoracic Surgery, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan

Requests for reprints: Adi F. Gazdar, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas TX, 75390-8593. Phone: 214-648-4921; Fax: 214-648-4940; E-mail: adi.gazdar{at}utsouthwestern.edu.

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non–small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P = 0.02) and adenocarcinoma histology (2.8%, 11 of 394; P = 0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Key Words: HER2 • EGFR • KRAS • mutation • lung cancer




This article has been cited by other articles:


Home page
 Cancer Res.Home page
H. Yamamoto, H. Shigematsu, M. Nomura, W. W. Lockwood, M. Sato, N. Okumura, J. Soh, M. Suzuki, I. I. Wistuba, K. M. Fong, et al.
PIK3CA Mutations and Copy Number Gains in Human Lung Cancers
Cancer Res., September 1, 2008; 68(17): 6913 - 6921.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. J. Gonzales, K. E. Hook, I. W. Althaus, P. A. Ellis, E. Trachet, A. M. Delaney, P. J. Harvey, T. A. Ellis, D. M. Amato, J. M. Nelson, et al.
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor
Mol. Cancer Ther., July 1, 2008; 7(7): 1880 - 1889.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M.-J. Ahn, B.-B. Park, J. S. Ahn, S. W. Kim, H.-T. Kim, J. S. Lee, J. H. Kang, J. Y. Cho, H. S. Song, S. H. Park, et al.
Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer?
Clin. Cancer Res., June 15, 2008; 14(12): 3860 - 3866.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Trowe, S. Boukouvala, K. Calkins, R. E. Cutler Jr., R. Fong, R. Funke, S. B. Gendreau, Y. D. Kim, N. Miller, J. R. Woolfrey, et al.
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
Clin. Cancer Res., April 15, 2008; 14(8): 2465 - 2475.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
N. Shivapurkar, V. Stastny, Y. Xie, C. Prinsen, E. Frenkel, B. Czerniak, F. B. Thunnissen, J. D. Minna, and A. F. Gazdar
Differential Methylation of a Short CpG-Rich Sequence within Exon 1 of TCF21 Gene: A Promising Cancer Biomarker Assay
Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 995 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al.
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
Cancer Res., January 15, 2008; 68(2): 571 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M.-E. Legrier, C.-P. H. Yang, H.-G. Yan, L. Lopez-Barcons, S. M. Keller, R. Perez-Soler, S. B. Horwitz, and H. M. McDaid
Targeting Protein Translation in Human Non Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
Cancer Res., December 1, 2007; 67(23): 11300 - 11308.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Beauclair, P Formento, J. Fischel, W Lescaut, R Largillier, E Chamorey, P Hofman, J. Ferrero, G Pages, and G Milano
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Ann. Onc., August 1, 2007; 18(8): 1335 - 1341.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. P. Piechocki, G. H. Yoo, S. K. Dibbley, and F. Lonardo
Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib In vitro and In vivo and Acquires Resistance through a Novel Point Mutation in the HER2/neu
Cancer Res., July 15, 2007; 67(14): 6825 - 6843.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Mounawar, A. Mukeria, F. Le Calvez, R. J. Hung, H. Renard, A. Cortot, C. Bollart, D. Zaridze, P. Brennan, P. Boffetta, et al.
Patterns of EGFR, HER2, TP53, and KRAS Mutations of p14arf Expression in Non-Small Cell Lung Cancers in Relation to Smoking History
Cancer Res., June 15, 2007; 67(12): 5667 - 5672.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cappuzzo, C. Ligorio, P. A. Janne, L. Toschi, E. Rossi, R. Trisolini, D. Paioli, A. J. Holmes, E. Magrini, G. Finocchiaro, et al.
Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial
J. Clin. Oncol., June 1, 2007; 25(16): 2248 - 2255.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. Xu and L. Neckers
Targeting the Molecular Chaperone Heat Shock Protein 90 Provides a Multifaceted Effect on Diverse Cell Signaling Pathways of Cancer Cells
Clin. Cancer Res., March 15, 2007; 13(6): 1625 - 1629.
[Full Text] [PDF]

Home page
 JCOHome page
A. F. Gazdar and M. J. Thun
Lung Cancer, Smoke Exposure, and Sex
J. Clin. Oncol., February 10, 2007; 25(5): 469 - 471.
[Full Text] [PDF]

Home page
 The OncologistHome page
L. Toschi and F. Cappuzzo
Understanding the New Genetics of Responsiveness to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Oncologist, February 1, 2007; 12(2): 211 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Ono and M. Kuwano
Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs
Clin. Cancer Res., December 15, 2006; 12(24): 7242 - 7251.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. P. Cunningham, H. Thomas, Z. Fan, and H. Modjtahedi
Responses of Human Colorectal Tumor Cells to Treatment with the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib.
Cancer Res., August 1, 2006; 66(15): 7708 - 7715.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Swanton, A. Futreal, and T. Eisen
Her2-targeted therapies in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4377s - 4383s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Johnson
Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
M. Sonobe, T. Manabe, H. Wada, and F. Tanaka
Lung Adenocarcinoma Harboring Mutations in the ERBB2 Kinase Domain
J. Mol. Diagn., July 1, 2006; 8(3): 351 - 356.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Shimamura, H. Ji, Y. Minami, R. K. Thomas, A. M. Lowell, K. Shah, H. Greulich, K. A. Glatt, M. Meyerson, G. I. Shapiro, et al.
Non-Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272.
Cancer Res., July 1, 2006; 66(13): 6487 - 6491.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Cappuzzo, L. Bemis, and M. Varella-Garcia
HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
N. Engl. J. Med., June 15, 2006; 354(24): 2619 - 2621.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Brambilla and S. Lantuejoul
Telomerase activation in adenocarcinoma-bronchioloalveolar carcinoma.
Eur. Respir. J., June 1, 2006; 27(6): 1079 - 1081.
[Full Text] [PDF]

Home page
 The OncologistHome page
S. Ramalingam and A. B. Sandler
Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
Oncologist, June 1, 2006; 11(6): 655 - 665.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Citri, D. Harari, G. Shohat, P. Ramakrishnan, J. Gan, S. Lavi, M. Eisenstein, A. Kimchi, D. Wallach, S. Pietrokovski, et al.
Hsp90 Recognizes a Common Surface on Client Kinases
J. Biol. Chem., May 19, 2006; 281(20): 14361 - 14369.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Calvo and J. Baselga
Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
J. Clin. Oncol., May 10, 2006; 24(14): 2158 - 2163.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S.-W. Han, T.-Y. Kim, Y. K. Jeon, P. G. Hwang, S.-A. Im, K.-H. Lee, J. H. Kim, D.-W. Kim, D. S. Heo, N. K. Kim, et al.
Optimization of Patient Selection for Gefitinib in Non-Small Cell Lung Cancer by Combined Analysis of Epidermal Growth Factor Receptor Mutation, K-ras Mutation, and Akt Phosphorylation
Clin. Cancer Res., April 15, 2006; 12(8): 2538 - 2544.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Y. S. Tam, L. P. Chung, W. S. Suen, E. Wang, M. C.M. Wong, K. K. Ho, W. K. Lam, S. W. Chiu, L. Girard, J. D. Minna, et al.
Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non-Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features
Clin. Cancer Res., March 1, 2006; 12(5): 1647 - 1653.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. S. Rao, N. Kremenevskaja, R. von Wasielewski, V. Jakubcakova, S. Kant, J. Resch, and G. Brabant
Wnt/{beta}-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 159 - 168.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Lee, Y. H. Soung, S. H. Seo, S. Y. Kim, C. H. Park, Y. P. Wang, K. Park, S. W. Nam, W. S. Park, S. H. Kim, et al.
Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
Clin. Cancer Res., January 1, 2006; 12(1): 57 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Yauch, T. Januario, D. A. Eberhard, G. Cavet, W. Zhu, L. Fu, T. Q. Pham, R. Soriano, J. Stinson, S. Seshagiri, et al.
Epithelial versus Mesenchymal Phenotype Determines In vitro Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients
Clin. Cancer Res., December 15, 2005; 11(24): 8686 - 8698.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
O. C. Ioachimescu and A. C. Mehta
From cystic pulmonary airway malformation, to bronchioloalveolar carcinoma and adenocarcinoma of the lung
Eur. Respir. J., December 1, 2005; 26(6): 1181 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. E.W. Cohen, M. W. Lingen, L. E. Martin, P. L. Harris, B. W. Brannigan, S. M. Haserlat, R. A. Okimoto, D. C. Sgroi, S. Dahiya, B. Muir, et al.
Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR
Clin. Cancer Res., November 15, 2005; 11(22): 8105 - 8108.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Takano, Y. Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, S. Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine, et al.
Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non-Small-Cell Lung Cancer
J. Clin. Oncol., October 1, 2005; 23(28): 6829 - 6837.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Davies, C. Hunter, R. Smith, P. Stephens, C. Greenman, G. Bignell, J. Teague, A. Butler, S. Edkins, C. Stevens, et al.
Somatic Mutations of the Protein Kinase Gene Family in Human Lung Cancer
Cancer Res., September 1, 2005; 65(17): 7591 - 7595.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Shibata, S. Uryu, A. Kokubu, F. Hosoda, M. Ohki, T. Sakiyama, Y. Matsuno, R. Tsuchiya, Y. Kanai, T. Kondo, et al.
Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features
Clin. Cancer Res., September 1, 2005; 11(17): 6177 - 6185.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Cappuzzo, M. Varella-Garcia, H. Shigematsu, I. Domenichini, S. Bartolini, G. L. Ceresoli, E. Rossi, V. Ludovini, V. Gregorc, L. Toschi, et al.
Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients
J. Clin. Oncol., August 1, 2005; 23(22): 5007 - 5018.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. J. Gilbertson
ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty
Oncologist, August 1, 2005; 10(7): 508 - 517.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. J. Kaye
A Curious Link Between Epidermal Growth Factor Receptor Amplification and Survival: Effect of "Allele Dilution" on Gefitinib Sensitivity?
J Natl Cancer Inst, May 4, 2005; 97(9): 621 - 623.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.